The US Surgical Matrices Market rebounded toward pre-COVID-19 levels in Q320 as the numbers of hernia and breast surgeries came closer to normal levels. The recovery was somewhat uneven, with Breast Matrices still off -8.6% YoY, while Hernia Matrices were closer to pre-COVID-19 levels, off -2.5% YoY.
As hospitals began to establish a new normal in the time of COVID-19, the US Surgical Matrices Market rebounded to lose only -4.6% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* (formerly Allergan) held on to its lead despite the effects of the pandemic, as its breast-heavy portfolio showed a slower return to normal. Becton Dickinson* (BD) lost less than AbbVie/Allergan, declining –3.5% YoY, as hernia procedures bounced back to normal levels a little faster.
Among the many topics covered in the comprehensive Q320 US Surgical Matrices Market Recap* are:
- Complete US Surgical Matrices Market Overview
- Companies' Revenue and Market Shares
- US Surgical Matrices Market Rebounds Toward Pre-COVID-19 Levels
- US Breast Matrices Market: Surgeries Resume
- US Hernia Repair Matrices Market: Coming Back From COVID-19
- Q320 Regulatory Events in the US Surgical Matrices Market
The US Surgical Matrices market bounced back in both the Breast Reconstruction and Hernia Repair segments, with procedures in both segments coming back toward normal in Q320. For Q320, the Breast segment mitigated its losses, losing only ...
Read the entire Q320 US Surgicla Matrices Market Recap including news, data, charts, company revenues and analysis*
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
